Long-term safety of BHV-7000 in epilepsy
Treatments studied
Part of Brain & nervous system clinical trials.
This study checks the long-term safety of BHV-7000 for people who already completed an earlier trial with this drug. You keep taking the same medicine while doctors watch for any side effects over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have finished the main (double-blind) phase of an earlier BHV-7000 study (BHV7000-302 or BHV7000-303).
- If you are a woman who could become pregnant, you need a negative urine pregnancy test at the start of this study.
- You should not have any ongoing side effects from the earlier study that would make continuing treatment risky.
- You should not have a new medical condition that could affect the study results or your safety, based on your doctor's judgment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called BHV-7000 for adults whose focal seizures (starting in one part of the brain) are not controlled by current treatments. The goal is to see if it can reduce seizures safely.
This study is a long-term follow-up for people with epilepsy who already completed a previous trial of the drug CB03-154. It checks if the drug remains safe and effective over more time.
This trial tests a new medication, CB03-154, to see if it is safe and can reduce seizures in adults with focal epilepsy. You may be able to join if you have had focal epilepsy for at least 2 years and are on a stable dose of 1 to 3 anti-seizure medications.
This study gives XEN1101 in an open-label way (everyone knows they’re getting the drug) to people who finished earlier epilepsy studies. It aims to see how the treatment continues to work and whether it’s safe over the long term.
This study tests a new once-daily pill called BHV-8000 in people who were recently diagnosed with early Parkinson's disease and are not yet on medication. The goal is to see if it can slow the progression of symptoms and improve quality of life.
This trial tests XEN1101 compared with a placebo (inactive pill) in people with focal-onset seizures that haven’t been fully controlled despite trying at least two anti-seizure medicines. If you qualify, you may help researchers see whether the study drug reduces seizure frequency and improves control.
Hear when a new Focal Epilepsy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.